

Automatisation totale en bactériologie diagnostique : réalité ou fantaisie ?

Dr A. CHERKAOUI, PhD-FAMH
Laboratoire de Bactériologie





ccCTA - 17 septembre 2021

There is no conflict of interest


- Conventional diagnostic work-up
- MALDI-TOF/MS
- Total Laboratory Automation
- Fully Automated solution for Antimicrobial Disk Diffusion Susceptibility Testing

Laboratoire de Bactériologie Hôpitaux universitaires de Genève





H0




Conventional diagnostic work-up

H48
Pathogens
ID and AST
results



Biochemistry testing methods for
identifying microorganisms
(time consuming and complex tasks)

Antimicrobial
Disk Diffusion
Susceptibility
Testing



These routine laboratory techniques ensure an accurate identification of
most microorganisms

BUT

• Costly



• require time



Conventional diagnostic work-up

STEP-1: Gram stain, samples inoculation on different culture media and incubation



> 1000 culture media per day / 4 Technologist (full time)

Conventional diagnostic work-up

STEPS 2 to 4: Incubation of culture media plates, Reading and Microbial identification



> 2000 culture media per day

Conventional diagnostic work-up

STEP-5: Antimicrobial susceptibility testing



> 100 AST per day / **1** Technologist (full time)



Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

Rodger D. MacArthur,¹ Mark Miller,² Timothy Albertson,³ Edward Panacek,³ David Johnson,⁴ Leah Teoh,⁵ and William Barchuk⁵


¹Wayne State University, Detroit, Michigan; ⁵Abbott Laboratories, Parsippany, New Jersey; ³University of California, Davis, Sacramento, California; and ²McGill University, Montreal, and ⁴Department of Medicine, Royal University Hospital, Saskatoon, Canada

As part of the Monoclonal Anti-TNF: A Randomized Controlled Sepsis (MONARCS) trial, which enrolled patients with suspected sepsis, we sought to determine whether adequate antibiotic therapy was associated with a decreased mortality rate. The study enrolled 2634 patients, 91% of whom received adequate antibiotic therapy. The mortality rate among patients given adequate antibiotic treatment was 33%, versus 43% among patients given inadequate treatment ($P < .001$). We conclude that adequate antibiotic therapy results in a significant decrease in the crude mortality rate among patients suspected of sepsis.



Impact of Inadequate Empirical Therapy on the Mortality of Patients with Bloodstream Infections: a Propensity Score-Based Analysis

Pilar Retamar,^a María M. Portillo,^a María Dolores López-Prieto,^b Fernando Rodríguez-López,^c Marina de Cueto,^a María V. García,^d María J. Gómez,^e Alfonso del Arco,^f Angel Muñoz,^g Antonio Sánchez-Porto,^h Manuel Torres-Tortosa,ⁱ Andrés Martín-Aspas,^j Ascensión Arroyo,^k Carolina García-Figueras,^b Federico Acosta,^l Juan E. Corzo,^m Laura León-Ruiz,ⁿ Trinidad Escobar-Lara,^o Jesús Rodríguez-Baño,^{a,p} and the SAEI/SAMPAC Bacteremia Group



Article


Mortality After Delay of Adequate Empiric Antimicrobial Treatment of Bloodstream Infection

Merel M. C. Lambregts^{1,*†}, Roos Wijnakker^{1,†}, Alexandra T. Bernards², Leo G. Visser¹, Saskia le Cessie³ and Mark G. J. de Boer¹

Misidentification of *Listeria monocytogenes* by the Vitek 2 System

Niall De Lappe, Ciara Lee, Jean O'Connor, Martin Cormican

National Salmonella, Shigella & Listeria Reference Laboratory, Medical Microbiology Department, University Hospital Galway, Galway, Ireland



Pizarro-Cerda et al. Cell 2006

Brucellose acquise au laboratoire

Inde

Patient aux urgences avec drainage d'un abcès pleural

- Envoi du prélèvement au labo sans autre indication
- Inoculation des milieux de culture en class 2 biosafety
- Absence de germe au Gram
- 72h, croissance de cocobacilles à Gram négatif
- Identification API 20 NE panel (BioMérieux):

Moraxella phenylpyruvica

Après 22 jours, identification définitive pour *Brucella* !!!

26 personnes travaillant dans laboratoire

19 physiquement présent

1 a « reniflé » les milieux de culture

6 ont manipulé (dont une femme enceinte)

Table 1. Serum titers of *Brucella melitensis* in exposed laboratory personnel (exposure between 27 June to 9 July).

Laboratory worker	Prophylaxis received	Observed titer(s) ^a							
		11 Jul	25 Jul	8 Aug	22 Aug	5 Sep	19 Sep	3 Oct	17 Oct
1	No	0	...	0	...	0	0
2 (HRI)	No	0	...	0	1:80; <1/160	1:320 ^c ; 1:1280 ^c

[Prevention of Laboratory-Acquired Brucellosis. CID 2004; 38: 119]

MALDI-TOF/MS








Figure 1. Schema showing the linear mode workflow in a MALDI-TOF MS system.





HCCA: alpha-Cyano-4-hydroxycinnamic acid

Comparison of Two Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Methods with Conventional Phenotypic Identification for Routine Identification of Bacteria to the Species Level[▼]

Abdessalam Cherkaoui,^{1*} Jonathan Hibbs,² Stéphane Emonet,¹ Manuela Tangomo,² Myriam Girard,² Patrice Francois,² and Jacques Schrenzel^{1,2}


Clinical Microbiology Laboratory¹ and Genomic Research Laboratory,² Service of Infectious Diseases, University of Geneva Hospitals (HUG), CH-1211 Geneva 14, Switzerland

Received 23 September 2009/Returned for modification 23 November 2009/Accepted 9 February 2010

Cost and timeliness estimates of Bruker-based identification

	Cost per isolate (\$US)		Turnaround time (hr)	
	Avg.	Total	Avg.	Total
High confidence MALDI-TOF MS (n=636)	\$0.50	\$318	0.08	53
Lower-confidence and Ambiguous MALDI-TOF MS (n=84)	\$10.50	\$882	24	2,016
Total cost:		\$1,200	Average time: 3 hrs	

Accuracy of MALDI-TOF MS identifications of 720 clinical isolates



Cost and timeliness estimates of conventional identification

	Cost per isolate (\$US)		Turnaround time (hr)	
	Avg.	Total	Avg.	Total
<i>E. coli</i> (n=216)	\$0.20	\$43	1	216
<i>S. aureus</i> (n=55)	\$1.50	\$83	1	55
Other (n=449)	\$10.00	\$4,490	24	10,776
All isolates (n=720)	Total cost:	\$4,616	Average time: 15 hrs	

Evaluation of Matrix-Assisted Laser Desorption–Time of Flight Mass Spectrometry for Rapid Identification of Beta-Hemolytic Streptococci⁷


Abdessalam Cherkaoui,^{1*} Stéphane Emonet,¹ José Fernandez,¹
Didier Schorderet,¹ and Jacques Schrenzel^{1,2}

Bacteriology Laboratory¹ and Genomic Research Laboratory, Department of Internal Medicine,² Service of Infectious Diseases, University of Geneva Hospitals (HUG), CH-1211 Geneva 14, Switzerland





TABLE 1. Accuracy of MALDI-TOF MS identification of 386 beta-hemolytic streptococcal isolates^a

Organism group (no. of isolates) and identification parameter	No. of isolates (%) found by:		
	MALDI-TOF MS identification with score of >2.0	Vitek2 identification	16S rRNA gene sequencing
<i>Streptococcus pyogenes</i> (52)			
Species correct	52 (100)	48 (92)	4 (7.7)
Major error	0	2 (3.8)	
Minor error	0	0	
No identification	0	2 (3.8)	
<i>Streptococcus agalactiae</i> (306)			
Species correct	306 (100)	269 (88)	37 (12)
Major error	0	2 (0.7)	
Minor error	0	32 (10.5)	
No identification	0	3 (1.0)	
<i>Streptococcus dysgalactiae</i> (28)			
Species correct	28 (100)	11 (39)	17 (6.1)
Major error	0	7 (25)	
Minor error	0	1 (3.6)	
No identification	0	9 (32)	



H0








H48
Pathogens
ID and AST
results



Biochemistry testing methods for
identifying microorganisms
(time consuming and complex tasks)

Antimicrobial
Disk Diffusion
Susceptibility
Testing






Automatic System for Colony Picking and MALDI-TOF Targets Preparation

Applications of MALDI-TOF mass spectrometry in clinical microbiology

- MALDI-TOF MS to identify rare pathogenic bacteria
- MALDI-TOF MS directly from positive blood culture - rapid identification protocols
- MALDI-TOF MS directly from urine samples
- MALDI-TOF-based subtyping as a tool for outbreak investigation
- Antibiotic resistance testing using MALDI-TOF MS
- ...

Total Laboratory Automation (TLA)



Step-1




Step-2



Step-3




Step-4




Step-5

- Step 1 Inoculation
- Step 2 Incubation
- Step 3 Reading
- Step 4 Identification
- Step 5 DD AST

The beginning of great changes in the Bacteriology Lab





Copan Diagnosis, Inc. www.Copanusa.com



DEONET factory, the Netherlands (Fot. ABB)



Progressive automation of Microbiology culture-based testing

Preamerical specimen management and processing : inoculation and steaking



The BD Kiestra™ Inoqua+
*2006

Total Laboratory Automation : clinical specimens processing, Incubation and culture media plates digital imaging



The BD Kiestra™ WCA system
*2012



The BD Kiestra™ TLA system
*2006




Copan WASP / *2006



Copan WASPLab
*2012

*First installation in routine diagnostic laboratory



Traditional Manual Process

Fully Automated Process







Gram Slide Preparation




WASP DT






SUIVANTE (SHIFT+N)
(2013) COPAN's
WASPLab





Individual plate shelves
ensure homogenous
environmental conditions
and excellent
thermal conductivity

At the image acquisition station a critical zero-hour image is recorded



TLA : Project management
and change management




Figure 1 Automation of the clinical bacteriology laboratory at Geneva University Hospitals: Specific steps executed and time dedicated to perform each of the project phases.

System-1 is composed of 2 WASP, 2 “CO2 (5%) atmosphere” and 1 “air atmosphere” incubators.
System-2 for AST is composed of 1 WASP, and 1/2 “air atmosphere” incubator.






Fig. 2 Number of laboratory technologists trained to perform bacteriology analyses on the WASPLabTM







Figure 3 Sequential implementation on the WASPLabTM of the various sample types referred to the bacteriology laboratory at Geneva University Hospitals between October 2018 and October 2019

CPS3, CHROMID[®] CPS[®] Elite; MRSAID, CHROMID[®] MRSA; GS, Blood agar; MAC, MacConkey agar; CNA, CNA agar; Choc, Chocolate agar; BLSEID, CHROMID[®] ESBL; OXA48, CHROMID[®] OXA-48



Laboratory efficiency improvement



TLA enables the reduction of the incubation times and allows earlier culture readings

Fully Automated solution for AST by **Disk Diffusion**



ELSEVIER

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Clinical Microbiology and Infection

journal homepage: www.clinicalmicrobiologyandinfection.com

Original article

Copan WASPLab automation significantly reduces incubation times and allows earlier culture readings

A. Cherkaoui ^{1,*}, G. Renzi ¹, N. Vuilleumier ^{2,3}, J. Schrenzel ^{1,4}

¹) Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland


²) Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland

³) Division of Laboratory Medicine, Department of Medical Specialties, Faculty of Medicine, Geneva, Switzerland

⁴) Genomic Research Laboratory, Division of Infectious Diseases, Department of Medical Specialties, Faculty of Medicine, Geneva, Switzerland




Code [002652525201] Time: 2019-02-21 17:41:56
Recording time: 0 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




0h

Choc
30 ul
Code [002652525201] Time: 2019-02-21 19:42:43
Recording time: 2 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




2h

Choc
30 ul
Code [002652525201] Time: 2019-02-21 20:43:11
Recording time: 3 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




3h

Choc
30 ul
Code [002652525201] Time: 2019-02-21 21:43:15
Recording time: 4 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



4h

Choc
30 ul
Code [002652525201] Time: 2019-02-21 23:42:43
Recording time: 6 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



6h

Code [002652525201] Time: 2019-02-22 17:42:43
Recording time: 24 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




24h

Choc
30 ul
Code [002652525201] Time: 2019-02-22 13:42:43
Recording time: 20 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




20h

Choc
30 ul
Code [002652525201] Time: 2019-02-22 09:42:58
Recording time: 16 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




16h

Choc
30 ul
Code [002652525201] Time: 2019-02-22 05:42:58
Recording time: 12 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



12h

Choc
30 ul
Code [002652525201] Time: 2019-02-22 01:42:45
Recording time: 8 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




8h

Code [002652525201] Time: 2019-02-22 23:42:43
Recording time: 30 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



30h

Choc
30 ul
Code [002652525201] Time: 2019-02-23 09:42:43
Recording time: 40 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



40h

Choc
30 ul
Code [002652525201] Time: 2019-02-23 19:42:43
Recording time: 50 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091




50h

Choc
30 ul
Code [002652525201] Time: 2019-02-24 05:42:43
Recording time: 60 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



60h

Choc
30 ul
Code [002652525201] Time: 2019-02-24 17:42:43
Recording time: 72 h 0 min.
Media type: BIOMERIEUX-chocolate_povyflex-43101
Light: Black background_with_backlight lev. 14
WL091



72h

Table 1: The incubation protocols, the culture media used for each sample type, and the number of samples included in the derivation set and in the independent validation set.

CPE: Carbapenemase-producing Enterobacteriaceae, MRSA : Methicillin-resistant *Staphylococcus aureus* , MSSA: Methicillin susceptible *Staphylococcus aureus* , ESBL : Extended-spectrum beta-lactamases; CNA agar: Colistin-Nalidixic Acid agar

Clinical sample types	WASP coupled to conventional incubation and manual diagnostic		WASPLab	
	Culture media type	Routine incubation period	Number of samples included in the derivation set	Number of samples included in the independent validation set
Urine specimens	CHROMID® CPS® Elite (BioMérieux, Geneva, Switzerland)	18h-24h and 48h	109	266
Genital tract specimens	Blood agar, chocolate agar, CNA agar, and MacConkey agar	24h and 48h	92	189
Non-sterile site specimens	Blood agar, chocolate agar, CNA agar, and MacConkey agar	24h, 48h and 72h	50	109
Nasal and inguinal/perineal screening-ESwabs for MRSA and MSSA	CHROMID® MRSA (BioMérieux) and SaSelect Medium (BioRad)	18h-24h and 48h	148	181
Rectal screening-ESwabs for ESBL-producer and CPE	CHROMID® ESBL (BioMérieux) coupled to CHROMID® OXA-48 (BioMérieux)	18h-24h and 48h	84	66
Total			483	811 / (1294 samples)

Table 7 : Definitive incubation protocols based on the derivation and validation studies


CPE: Carbapenemase-producing *Enterobacteriaceae* , MRSA : Methicillin-resistant *Staphylococcus aureus* , MSSA: Methicillin susceptible *Staphylococcus aureus* , ESBL : Extended-spectrum beta-lactamases

WASPLab				
Routine incubation period	Clinical samples type	Incubation time		
		Picture at T0	Intermediate incubation time	Final incubation time
18h-24h and 48h	Urine specimens	Yes	18h	24h
24h and 48h	Genital tract specimens	Yes	16h	28h
24h, 48h and 72h	Non-sterile site specimens	Yes	16h	28h
18h-24h and 48h	Nasal and inguinal/perineal screening-ESwabs for MRSA and MSSA	Yes	No	18h
18h-24h and 48h	Rectal screening-ESwabs for ESBL-producer and CPE	Yes	No	16h

Automated Incubation and Digital Image Analysis of Chromogenic Media Enables Rapid Detection of Vancomycin-Resistant Enterococcus

Abdessalam Cherkaoui^{1*}, Gesuele Renzi¹, Yannick Charretier², Dominique S. Blanc^{3,4}, Nicolas Vuilleumier^{5,6} and Jacques Schrenzel^{1,2}

¹ Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland, ² Genomic Research Laboratory, Division of Infectious Diseases, Department of Medical Specialties, Faculty of Medicine, Geneva, Switzerland, ³ Service of Hospital Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland, ⁴ Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland, ⁵ Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland, ⁶ Division of Laboratory Medicine, Department of Medical Specialties, Faculty of Medicine, Geneva, Switzerland




Clinical sample type	Solid culture media type	Plating volume, µl	Incubation times			
			Picture at T0	First intermediate incubation time, hr	Second intermediate incubation time, hr	Final incubation time, hr
Rectal screening-Eswab for VRE	CHROMID® VRE (BioMérieux)	30	Yes	18	24	30







Rapid identification by MALDI-TOF/MS and antimicrobial disk diffusion susceptibility testing for positive blood cultures after a short incubation on the WASPLab

Abdessalam Cherkaoui¹ • Gesuele Renzi¹ • Nouria Azam¹ • Didier Schorderet¹ • Nicolas Vuilleumier^{2,3} • Jacques Schrenzel^{1,4}

Received: 18 November 2019 / Accepted: 12 January 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020



Graph adapted from AdvanDx



Streptococcus pyogenes

Table 1 Minimal incubation times required for MALDI-TOF /MS-based species identification and AST by disk diffusion from short subcultures growing on solid media incubated on the Copan WASPLab

Microorganisms		Number of non-duplicate strains analyzed	Incubation time required for MALDI-TOF/MS-based species identification from short subcultures growing on solid media (hours)	Incubation time required for 0.5 McFarland suspension from short subcultures growing on solid media for AST by disk diffusion (hours)
Enterobacteriaceae	<i>Escherichia coli</i>	20	2	2
	<i>Klebsiella pneumoniae</i>	20	2	2
	<i>Proteus mirabilis</i>	20	2	2
	<i>Salmonella</i>	20	3	3
Non-fermenting Gram-negative bacilli	<i>Pseudomonas aeruginosa</i>	20	3	3
	<i>Stenotrophomonas maltophilia</i>	20	4	4
	<i>Acinetobacter</i> spp.	20	4	4
	<i>Burkholderia cepacia</i>	20	8	8
Gram-negative coccobacilli and othe Gram-negative bacilli	<i>Haemophilus influenzae</i>	20	6	6
	<i>Pasteurella</i> spp.	20	4	4
	<i>Aeromonas</i> spp.	20	3	3
<i>Staphylococcus</i>	<i>Staphylococcus aureus</i>	20	4	4
	<i>Staphylococcus epidermidis</i>	20	4	4
<i>Streptococcus</i>	<i>Streptococcus pneumoniae</i>	20	3	4
	<i>Streptococcus agalactiae</i>	20	3	4
	<i>Streptococcus mitis</i>	20	4	6
	<i>Streptococcus pyogenes</i>	20	3	4
Nutritionally deficient bacteria	<i>Abiotrophia</i>	20	6	8
	<i>Granulicatella adiacens</i>	20	6	8
<i>Enterococcus</i>	<i>Enterococcus faecalis</i>	20	3	3
	<i>Enterococcus faecium</i>	20	3	3
Gram-positive aerobic bacilli	<i>Listeria monocytogenes</i>	20	4	6
	<i>Bacillus</i> spp.	20	4	4
	<i>Corynebacterium</i> spp.	20	16	16
Yeast	<i>Candida glabrata</i>	20	6 (sufficient yeast biomass but no reliable identification)	
	<i>Candida albicans</i>	20		

Impact of total laboratory automation on turnaround times for urine cultures and screening specimens for MRSA, ESBL, and VRE carriage: retrospective comparison with manual workflow

Abdessalam CHERKAOU^{1*}, Gesuele RENZI¹, Romain MARTISCHANG¹, Stephan HARBARTH¹,
Nicolas VUILLEUMIER¹, Jacques Schrenzel¹

Impact of total laboratory automation on turnaround-time for culture-based bacteriological testing

Clinical sample type	Solid culture media type	Number of samples included in this study		% of positive samples		Plating volume, µl	Time points for digital images acquisition on WASPLab				Ref.
		2017	2019	2017	2019		Picture at T0	First time point, hr	Second time point, hr	Final time point, hr	
Urine specimens	CHROMID® CPS® Elite (BioMérieux)	19937	18226	51% (10080/19937)	51% (9343/18226)	10	Yes	18	No	24	[1]
Nasal and inguinal/perineal screening-Eswab for MRSA	CHROMID® MRSA (BioMérieux)	18464	15905	4% (751/18464)	5% (826/15905)	30	Yes	No	No	18	[1]
Rectal screening-Eswab for ESBL	CHROMID® ESBL (BioMérieux)	7803	8643	27% (2140/7803)	25% (2198/8643)	30	Yes	No	No	16	[1]
Rectal screening-Eswab for VRE	CHROMID® VRE (bioMérieux)	1973	7464	2% (45/1973)	0.8% (58/7464)	30	Yes	18	24	30	[2]


Table 1 Workup of bacterial culture, samples included in this study, and analysis parameters on the WASPLab based on previous studies.

1) Cherkaoui et al. Clinical Microbiology and Infection April 2019


2) Cherkaoui et al. Frontiers in Cellular and Infection Microbiology Nov. 2019

Turnaround time (from reception of samples to when the result is released to the ordering provider) for nasal and inguinal/perineal screening-ESwab for methicillin-resistant *Staphylococcus aureus* (MRSA) by culture

MRSA negative samples




MRSA positive samples




MRSA		Median TAT (hr)
Negative samples	2017	50.4
	2019	25.8
Positive samples	2017	70.1
	2019	70.3

Turnaround time (from reception of samples to when the result is released to the ordering provider) for rectal screening-ESwab for extended-spectrum beta-lactamases (**ESBLs**) by culture

ESBL negative samples




ESBL positive samples



ESBL		Median TAT (hr)
Negative samples	2017	49.8
	2019	42
Positive samples	2017	68
	2019	73.4


Turnaround time (from reception of samples to when the result is released to the ordering provider) for rectal screening-ESwab for vancomycin-resistant *Enterococcus* (VRE) by culture




VRE		Median TAT (hr)
Negative samples	2017	50.6
	2019	45.7
Positive samples	2017	102
	2019	92.2

Turnaround time (from reception of sample to when the result is released to the ordering provider) for a **urine culture**

Urine negative samples



Urine positive samples



Urine		Median TAT (hr)
Negative samples	2017	51.3
	2019	27.3
Positive samples	2017	54.8
	2019	52.5

TABLE 2 | Turnaround-times (from reception of samples to delivery of the culture results).

	Year	Urine cultures (h)		Screening for MRSA carriage (h)		Screening for ESBL carriage (h)		Screening for VRE carriage (h)	
Negative samples	2017	52.1	$P < 0.001$	50.7	$P < 0.001$	50.2	$P < 0.001$	50.6	$P < 0.001$
	2019	28.3		26.3		43.0		45.7	
Positive samples	2017	56.2	$P < 0.001$	69.2	$P = 0.053$	72.0	$P < 0.001$	102.0	$P = 0.087$
	2019	54.0		70.2		74.4		92.2	

Fully Automated solution for Antimicrobial Disk Diffusion Susceptibility Testing




AMERICAN
SOCIETY FOR
MICROBIOLOGY

Journal of
Clinical Microbiology®

BACTERIOLOGY



Performance of Fully Automated Antimicrobial Disk Diffusion Susceptibility Testing Using Copan Wasp Colibri Coupled to the Radian In-Line Carousel and Expert System

 Abdessalam Cherkaoui,^a Gesuele Renzi,^a Nicolas Vuilleumier,^b Jacques Schrenzel^{a,c}

^aBacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland

^bDivision of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland


^cGenomic Research Laboratory, Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

September 2021 Volume 59 Issue 9 e00777-21



Versus





2) Colibri™

The AST inoculum is prepared in strict accordance with the manufacturer's instructions



1) WASPLab® : digital plate images



To capture the relevant heterogeneity profiles for the same strain, the minimum number of pickpoints required by the system to prepare the AST inoculum is defined as follows :


- Six different pickpoints for Gram positive bacteria
- Four different pickpoints for Gram negative bacteria




3) WASP™ : The AST inoculum (2x30 µl loop/spreader) is spread over the entire surface of the round Mueller-Hinton agar plate according to the defined AST streaking pattern

4) Radian™ in Line Carousel: distributes the antibiotic discs






Traditional Manual Process



Fully Automated Process



6) Radian™ Expert System: Automatic reading of the inhibition zone diameters and AST interpretation for *Pseudomonas aeruginosa* strain



Heteroresistant populations (colonies visible within the inhibition halo, red arrow)



5) WASPLab® AST Line :
AST plates are digitized after 16 hours of incubation

Figure-1 (Parts 1 to 6): Workflow of a fully automated solution for antimicrobial disk diffusion susceptibility testing (Colibri™, WASP™, Radian™ in-Line Carousel, and Radian™ Expert System)

Colibri™ prepares the inocula for 10 strains within 21 min

AST Line (WASP™ + Radian™ in Line Carousel) executes AST for 10 strains (i.e. 40 media plates and 200 antibiotic discs) within 44 min

Antibiotics	Resistance rate % (no. of isolates)	Categorical agreement between the compared methods (%)	Colibri™ coupled to Radian™		VITEK 2® system	
			Very major error	Major error	Very major error	Major error
Enterobacterales species (n=292)						
Ampicillin	66 (193)	100				
Amoxicillin/Clavulanate	37 (108)	99.7		1		
Piperacillin/Tazobactam	21 (62)	98.6		2	2	
Cefuroxime	25 (73)	100				
Ceftazidime	22 (63)	99.3		2		
Ceftriaxone	22 (63)	99.3		2		
Cefepime	19 (56)	99		1	3	
Imipenem	6 (18)	98.6		2	1	1
Meropenem	7 (19)	99.7			1	
Ertapenem	17 (49)	97.6		3	4	
Amikacin	7 (19)	99.7			1	
Gentamicin	15 (45)	99.7		1		
Norfloxacin	35 (101)	100				
Ciprofloxacin	29 (85)	99.3				2
Co-trimoxazole	35 (103)	99.7		1		

<i>Pseudomonas aeruginosa</i> (n=198)						
Piperacillin	43 (85)	94	1		11 (incl. 5*)	
Piperacillin/Tazobactam	33 (65)	98.5			1	2
Ceftazidime	28 (56)	99.5		1		
Cefepime	28 (55)	99		1	1*	
Imipenem	30 (60)	98.5	1		2*	
Meropenem	27 (53)	98			4*	
Amikacin	24 (47)	99.5				1
Gentamicin	21 (42)	99				2
Tobramycin	23 (46)	100				
Ciprofloxacin	25 (49)	99.5				1
Levofloxacin	31 (61)	99			2 (incl. 1*)	


*Presence of colonies within the inhibition halo (heteroresistance detected only by disk diffusion)

The overall categorical agreements between the two compared methods

99.3% (4350/4380; 95% CI 99% to 99.5%)

98.6% (2147/2178; 95% CI 98.0% to 99.0%)

The most important cause of the very major errors encountered on the Vitek 2 for *P. aeruginosa* (62%, 13/21) was related to the presence of heteroresistant populations



Antibiotics	Resistance rate % (no. of isolates)	Categorical agreement between the compared methods (%)	Colibri™ coupled to Radian™		VITEK 2® system	
			Very major error	Major error	Very major error	Major error
<i>Staphylococcus</i> spp. (n=185 including 107 <i>Staphylococcus aureus</i> and 78 Coagulase-negative staphylococci)						
Cefoxitine	32 (60)	100			<div>1</div> <div>10</div>	
Gentamicin	21 (39)	100				
Ciprofloxacin	32 (60)	99.5				
Clindamycin	29 (53)	100				
Erythromycin	34 (62)	100				
Fusidic acid	26 (48)	100				
Co-trimoxazole	23 (42)	94.6				
Rifampicin	3 (6)	100				
Tigecyclin	0	100				
Linezolid	0	100				
<i>Enterococcus</i> spp. (n=43 including 38 <i>Enterococcus faecalis</i> and 5 <i>Enterococcus faecium</i>)						
Ampicillin	9 (4)	97.7		1		
Imipenem	9 (4)	97.7			1	
Gentamicin	9* (4)	100				
Linezolid	0	100				
Teicoplanin	0	100				
Vancomycin	0	100				
Tigecycline	0	100				
Nitrofurantoin	0**	100				
*High level of gentamicin resistance / **only <i>Enterococcus faecalis</i> isolates were included						

*High level of gentamicin resistance / **only *Enterococcus faecalis* isolates were included

The overall categorical agreements between the two compared methods

99.4% (1,839/1,850; 95% CI 98.9% to 99.7%)

These very major errors were reported only for coagulase-negative staphylococci (one *S. hominis* and nine *S. epidermidis*)
No strictly explication has been found

99.4% (342/344; 95% CI 97.9% to 99.8%)

Isolates tested (no. of strains)	Colibri coupled to Radian AST line		VITEK 2 system	
	Cost (EUR)		Cost (EUR)	
	Avg per isolate	Total	Avg per isolate	Total
Enterobacterales (292)	4.6	1343.2	8	2336
<i>Pseudomonas aeruginosa</i> (198)	3.18	629.6	8	1584
<i>Staphylococcus</i> spp. (185)	3.05	564.3	8	1480
<i>Enterococcus</i> spp. (43)	2.79	120	8	344
Total		2657.1		5744

Table-3 : Consumable costs estimate of the AST performed by the two compared methods

For AST by Colibri coupled to Radian AST line, we included only the costs of the media plates and of the specific panel of antibiotic discs tested

For the AST by VITEK 2, we included only the costs of the AST cards

Conclusions

The Colibri coupled to the Radian provide a fully automated solution for AST by disk diffusion with an accuracy that is equal to or better than that of the Vitek 2 system.

By implementing the full automation of AST process in a stepwise manner (IT development, validation of the performances, staff training, and then routine implementation) we have become able to reach **97% (95 to 110 AST panels per day / 270 to 300 plates)** of our routine AST panels performed by **the Colibri coupled to the Radian within 5 months.**

TABLE 3 Hallmarks of the phenotypic AST methods compared in this study

Colibri coupled to Radian	VITEK 2 system
Fully automated method	Semiautomated method
Easy to change the antibiotics tested	
Greatest flexibility and cost-effectiveness	Less flexible and more expensive (susceptibility cards)
Reliable for detecting heteroresistant subpopulations	Low sensitivity for the detection of heteroresistant subpopulations
Easy to see test failures (e.g., mixed inoculum)	Purity check plates are mandatory (more consumable and additional workload)
More accurate detection of new resistance mechanisms	Problems in detecting some patterns of carbapenemases (e.g., OXA-48-like producers)
Applicable to many fastidious organisms	The range of drug dilution is usually very narrow
Inability to provide precise data regarding the level of an organism's resistance or susceptibility	Provides a good approximation of the MIC

Impact clinique de l'automatisation...

- Valeur médicale
 - Réduire les temps de rendu de résultats médicalement actionnables
 - Détection / exclusion de pathogènes MDRO
 - Identification rapide des pathogènes
 - Antibiogrammes rapides

Merci pour votre attention